A large library based on a novel (CH2) scaffold: Identification of HIV-1 inhibitors

Biochemical and Biophysical Research Communications

Volumn 387, Issue 2, 2009, Pages 387-392

  Xiao, Xiaodong ^a   Feng, Yang ^a   Vu, Bang K ^a   Ishima, Rieko ^b   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody library; CH2; HIV; Human; Phage display; Scaffold

Indexed keywords

AMINO ACID DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BINDING PROTEIN M1A1; CD4 ANTIGEN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN; IMMUNOGLOBULIN CH2; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DNA LIBRARY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; PROTEIN STRUCTURE, TERTIARY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67949120214     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.07.044     Document Type: Article

References (25)

1. Dimitrov D.S., and Marks J.D. Therapeutic antibodies: current state and future trends-is a paradigm change coming soon?. Meth. Mol. Biol. 525 (2009) 1-27
2. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 18 (2007) 295-304
3. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
4. Dimitrov D.S. Engineered CH2 domains (nanoantibodies). mAbs 1 (2009) 26-28
5. Vu B., Walsh J., Dimitrov D.S., and Ishima R. Dynamics of antibody domains studied by solution NMR. Meth. Mol. Biol. 525 (2009) 533-544
6. Gong R., Vu B.K., Feng Y., Prieto D.A., Dyba M.A., Walsh J.D., Prabakaran P., Veenstra T.D., Tarasov S.G., Ishima R., and Dimitrov D.S. Engineered human antibody constant domains with increased stability. J. Biol. Chem. 284 (2009) 14203-14210
7. Duncan A.R., and Winter G. The binding-site for Clq on Igg. Nature 332 (1988) 738-740
8. Choudhry V., Zhang M.Y., Sidorov I.A., Louis J.M., Harris I., Dimitrov A.S., Bouma P., Cham F., Choudhary A., Rybak S.M., Fouts T., Montefiori D.C., Broder C.C., Quinnan G.V., and Dimitrov D.S. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363 (2007) 79 Corrigendum 368 (2007) 431
9. Arnold K., Bordoli L., Kopp J., and Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22 (2006) 195-201
10. J. Hsin, A. Arkhipov, Y. Yin, J.E. Stone, K. Schulten, Using VMD: an introductory tutorial, Curr. Protoc. Bioinform. 2008 (Chapter 5; unit 5.7).
11. Koide A., Bailey C.W., Huang X., and Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J. Mol. Biol. 284 (1998) 1141-1151
12. Fellouse F.A., Wiesmann C., and Sidhu S.S. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc. Natl. Acad. Sci. USA 101 (2004) 12467-12472
13. Chen W., Zhu Z., Feng Y., Xiao X., and Dimitrov D.S. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J. Mol. Biol. 382 (2008) 779-789
14. de Haard H.J., van Neer N., Reurs A., Hufton S.E., Roovers R.C., Henderikx P., de Bruine A.P., Arends J.W., and Hoogenboom H.R. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274 (1999) 18218-18230
15. Beers R., Chowdhury P., Bigner D., and Pastan I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin. Cancer Res. 6 (2000) 2835-2843
16. Goodin J.L., Nellis D.F., Powell B.S., Vyas V.V., Enama J.T., Wang L.C., Clark P.K., Giardina S.L., Adamovicz J.J., and Michiel D.F. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. Protein Exp. Purif. 53 (2007) 63-79
17. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
18. Darbha R., Phogat S., Labrijn A.F., Shu Y., Gu Y.J., Andrykovitch M., Zhang M.Y., Pantophlet R., Martin L., Vita C., Burton D.R., Dimitrov D.S., and Ji X.H. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 43 (2004) 1410-1417
19. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., and Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 310 (2005) 1025-1028
20. Radaev S., Motyka S., Fridman W.H., Sautes-Fridman C., and Sun P.D. The structure of a human type III Fc gamma receptor in complex with Fc. J. Biol. Chem. 276 (2001) 16469-16477
21. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., and Sodroski J. Characterization of conserved human-immunodeficiency-virus Type-1 Gp120 neutralization epitopes exposed upon Gp120-Cd4 binding. J. Virol. 67 (1993) 3978-3988
22. Moulard M., Phogat S.K., Shu Y., Labrijn A.F., Xiao X.D., Binley J.M., Zhang M.Y., Sidorov I.A., Broder C.C., Robinson J., Parren P.W.H.I., Burton D.R., and Dimitrov D.S. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. USA 99 (2002) 6913-6918
23. Hoffman T.L., LaBranche C.C., Zhang W.T., Canziani G., Robinson J., Chaiken I., Hoxie J.A., and Doms R.W. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. USA 96 (1999) 6359-6364
24. Zhang P.F., Bouma P., Park E.J., Margolick J.B., Robinson J.E., Zolla-Pazner S., Flora M.N., and Quinnan G.V. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J. Virol. 76 (2002) 644-655
25. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., Binley J., Vivona V., Grundner C., Huang C.C., Venturi M., Petropoulos C.J., Wrin T., Dimitrov D.S., Robinson J., Kwong P.D., Wyatt R.T., Sodroski J., and Burton D.R. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gpl120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77 (2003) 10557-10565